RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 AC and Weekly Paclitaxel Improve Outcomes in TNBC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 56
SP 7
OP 8
DO 10.1177/1559897715571072
UL http://mdc.sagepub.com/content/14/56/7.abstract
AB This article presents the 10-year results of a study comparing taxane type and schedule as a component of adjuvant chemotherapy in localized breast cancer. When administered after doxorubicin-cyclophosphamide, weekly paclitaxel and every-3-weeks docetaxel significantly improved outcomes in the entire study population, while weekly paclitaxel improved outcomes in triple-negative breast cancer.